Harbor Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Harbor Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-23,978	Closed	-$2.58M	–	1343
2024 Q2	$2.58M	Sell	23,978 -2,999	-11%	-$300K	0.2%	145
2024 Q1	$2.56M	Sell	26,977 -3,536	-12%	-$303K	0.33%	51
2023 Q4	$2.81M	Sell	30,513 -1,971	-6%	-$128K	0.54%	31
2023 Q3	$1.63M	Buy	32,484 +8,131	+33%	+$434K	0.35%	68
2023 Q2	$1.54M	Buy	+24,353	New	+$1.32M	0.31%	81
2022 Q4	–	Sell	-4,575	Closed	-$301K	–	161
2022 Q3	$301K	Sell	4,575 -7,760	-63%	-$498K	0.28%	73
2022 Q2	$623K	Sell	12,335 -153	-1%	-$8.96K	0.47%	65
2022 Q1	$798K	Sell	12,488 -1,826	-13%	-$131K	0.38%	70
2021 Q4	$1.53M	Buy	+14,314	New	+$1.5M	0.56%	56

Other funds holding BPMC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Harbor Capital Advisors's BPMC Position: Q3 2024 in Review

Harbor Capital Advisors sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 23,978 shares — an estimated $2.58M sold.

Harbor Capital Advisors first reported a position in BPMC in Q4 2021 and held it in 9 quarters. The position peaked at $2.81M in Q4 2023. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

Harbor Capital Advisors reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
Harbor Capital Advisors sold 23,978 Blueprint Medicines shares in Q3 2024, an estimated $2.58M.
Harbor Capital Advisors first reported a position in Blueprint Medicines in Q4 2021 and held it in 9 quarters.
Harbor Capital Advisors's Blueprint Medicines position peaked at $2.81M in Q4 2023.
319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Harbor Capital Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.